Company intelligence / Profile preview

Reflex Medical

Hayward, California, United States

Ownership: Private
Employees: ~245
Development stage: Other

Overview

RefleXion completed the first-ever patient treatment with SCINTIX biology-guided radiotherapy on the RefleXion X1 machine at Stanford Medicine Cancer Center in August 2023. The FDA granted De Novo marketing authorization and Breakthrough Device designation for lung tumors. The technology has received FDA clearance for treating lung and bone tumors, and the RefleXion X1 is also cleared for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and intensity modulated radiotherapy (IMRT).

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalDevice
Industry: Therapeutic Medical Devices

Partnerships

Stanford Medicine Cancer CenterCity of Hope Comprehensive Cancer Center

Beyond the preview

Go deeper on Reflex Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reflex Medical.

Explore the full profile